Two medicines accepted for use by NHS Scotland
Medicines for blood cancer and a rare muscle disorder will be made available for NHS patients
Read More
Tag: venetoclax
AbbVie’s Venclyxto shows promise as AML treatment
The drug is already on the market to treat chronic lymphocytic leukaemia (CLL)
Read More
AbbVie, Roche present positive Venclyxto results at ASCO
Venclyxto is a first-in-class targeted medicine designed to selectively bind and inhibit the B-cell lymphoma-2 protein.
Read More
Trial results show promise for chemo-free future treatment
95% of those treated in the study were found to have a complete remission rate.
Read More
FDA places partial hold on clinical trials of venetoclax for multiple myeloma
US regulators have placed a partial clinical hold on all trials assessing venetoclax for multiple myeloma after a higher than expected number of patient deaths.
Read More
Venetoclax gets NICE approval for chronic lymphocytic leukaemia
The National Institute for Health and Care Excellence (NICE) has recommended AbbVie’s Venclyxto to benefit thousands of adults with chronic lymphocytic leukaemia.
Read More
Green light for Roche/AbbVie’s chemo-free CLL treatment combo
Roche says a combination of Venclyxto and MabThera has been approved in the European Union for people with previously treated chronic lymphocytic leukaemia.
Read More
AbbVie’s Venclyxto hit with NICE rejection
Draft guidelines do not recommend NHS use of AbbVie’s Venclyxto for treating relapsed or refractory chronic lymphocytic leukaemia (CLL).
Read More
Roche’s Venclexta filed in the US for acute myeloid leukemia
Roche group Genentech has filed an application to market Venclexta in the US for acute myeloid leukemia (AML).
Read More
AbbVie unveils high undetectable disease rates for venetoclax/rituximab combo
AbbVie has unveiled new data showing high and durable undetectable minimal residual disease rates in patients with chronic lymphocytic leukaemia treated with venetoclax in combination with rituximab.
Read More
US nod for Venclexta/Rituxan combo
US regulators have approved a combination of AbbVie and Roche’s Venclexta in combination with Roche/Biogen’s Rituxan (rituximab) to treat chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL).
Read More
NEJM publishes venetoclax/rituximab data
A combination of venetoclax and rituximab being developed by AbbVie and Roche/Genentech significantly improved progression-free survival (PFS) in patients with chronic lymphocytic leukaemia (CLL), shows data published by the New England Journal of Medicine.
Read More
- Liverpool and McMaster University announce £300,000 strategic research partnership
- Study finds link between malaria parasites developing antimalarial drug resistance
- Researchers develop ‘digital twin’ heart models to better monitor PAH NHS patients
- Closed Loop and Pharmanovia investigate precision medicine combination in hypertension
- US study reveals interferon combinations cause lupus symptoms and affect treatment
